OncoMatch/Clinical Trials/NCT07276789
Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer
Is NCT07276789 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies LS301-IT 0.1 mg/kg for non small cell lung cancer (nsclc).
Treatment: LS301-IT 0.1 mg/kg — The aim of this Phase 2 study is to investigate the efficacy and safety of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by intravenous (IV) infusion in patients undergoing VATS (Video-Assisted Thoracoscopic Surgery) or RATS (Robotic-Assisted Thoracoscopic Surgery) resection of Stage I-II non-small cell lung cancer (NSCLC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Prior therapy
Cannot have received: radiation therapy
Lab requirements
Kidney function
Patients with impaired renal function [excluded]
Liver function
Total bilirubin level ≤ 1.5 times upper limit; AST/SGOT and ALT/SGPT ≤ 2.5 times the upper limit of normal (ULN)
Cardiac function
History, or presence in the ECG at Screening, of any clinically significant abnormalities including cardiac conduction abnormalities [excluded]
Total bilirubin level >1.5 times upper limit; AST/SGOT and ALT/SGPT > 2.5 times the upper limit of normal (ULN); Patients with impaired renal function [excluded]; History, or presence in the ECG at Screening, of any clinically significant abnormalities including cardiac conduction abnormalities [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Pennsylvania · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify